Diagnostics
Cure8 research brief
Why This Matters
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure markers can help monitor disease activity and response to treatment without invasive testing.
Who Should Pay Attention
Pediatric IBD patients and caregivers; pediatric gastroenterologists; researchers interested in IBD biomarkers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study looked at the C‑reactive protein-to‑albumin ratio (CAR) in 97 children with IBD (79 with Crohn’s disease, 18 with ulcerative colitis) from a single center, using retrospective data from diagnosis through one year.
CAR was higher in pediatric Crohn’s disease than ulcerative colitis, correlated with other inflammation measures (ESR, fecal calprotectin), clinical and endoscopic activity in Crohn’s, and fell from diagnosis to one‑year follow‑up in both remission and relapse groups.
However, CAR did not outperform CRP alone for distinguishing Crohn’s from ulcerative colitis in this sample.
The paper suggests CAR may be useful as a marker of disease activity and for serial monitoring in pediatric Crohn’s disease, but the study is retrospective, from one center, and the ulcerative colitis subgroup was small, limiting conclusions about UC and diagnostic discrimination.
If you track lab markers over time, CAR appears to change with treatment and disease course in this cohort, but current evidence does not show it is clearly superior to CRP alone for telling CD from UC.
Keep In Mind
Study is retrospective from a single center (n=97) with a small UC subgroup (n=18); CAR correlated with inflammatory markers and disease activity but did not outperform CRP for diagnostic discrimination. Findings are hypothesis‑generating and need prospective validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDiagnostics
PublisherMDPI AG
AuthorsJihye Kim, You Ie Kim, Sang Yong Kim
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 17, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.